Send to

Choose Destination
Endocr Relat Cancer. 2011 Jun 8;18(3):R79-89. doi: 10.1530/ERC-10-0162. Print 2011 Jun.

A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.

Author information

Department of Medical Oncology, Paul Strauss Cancer Center, and University of Strasbourg, 3 rue de la Porte de l'Hôpital - BP42, F-67065 Strasbourg, France.


The introduction of aromatase inhibitors (AI) has provided more options for adjuvant treatment of postmenopausal women; they are associated with improved disease-free survival, but less commonly with improvements in overall survival. Current evidence suggests that women at high risk of recurrence, especially those with node-positive disease, should receive an AI for 2 years as part of their treatment, but routine prescription of AIs to postmenopausal patients with low-risk disease is not appropriate. Not only the expected benefits but also the specific toxicity of the prescribed hormone therapy, and its cost, should be considered when selecting treatment.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center